AGO3

Across TCGA pan-cancer cohorts, AGO3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGO3 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher AGO3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGO3 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

SKCM, PRAD, and CHOL are the cancer types where AGO3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.075	0.619	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	DFS	Median	All	1.000	0.507	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGO3–SKCM (DFS)

Open the SKCM breakdown →